Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Report Overview
Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. It mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. The Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) pipeline drugs market research report outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, and Cardiovascular which include indications of Cognitive Disorders, Schizophrenia, Alzheimer’s Disease, Anxiety Disorders, Autism, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Down Syndrome, Epilepsy, Ischemic Stroke, Mild Cognitive Impairment, Panic Disorders, Pervasive Developmental Disorder (PDD), Traumatic Brain Injury and Unspecified Genetic Disorders. Furthermore, this report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are the central nervous system, genetic disorders, and cardiovascular. In 2022, the central nervous system was the leading therapy area in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)
For more therapy area insights into the GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market, download a free report sample
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Antagonist) and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Agonist). In 2022, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Antagonist) was the leading mechanism of action in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Analysis, by Mechanism of Actions, 2022 (%)
For more mechanism of action insights into the GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market, download a free report sample
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Segmentation by Routes of Administration
The key route of administration in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market is oral.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule type in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market is small molecule.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market- Competitive Landscape
The leading companies in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are AgeneBio Inc, Anvyl LLC, Cerevel Therapeutics Holdings Inc, F. Hoffmann-La Roche Ltd, Les Laboratoires Servier SAS, Ono Pharmaceutical Co Ltd, and Saniona AB. In 2022, F. Hoffmann-La Roche Ltd dominated the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market.
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market, by Companies, 2022 (%)
To know more about the leading companies in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market, download a free report sample
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 Pipeline Drugs Market Report Overview
Key Therapy Areas | Central Nervous System, Genetic Disorders, and Cardiovascular |
Key Mechanism of Actions | Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Antagonist) and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Agonist) |
Key Routes of Administration | Oral |
Key Molecule Types | Small Molecule |
Key Companies | AgeneBio Inc, Anvyl LLC, Cerevel Therapeutics Holdings Inc, F. Hoffmann-La Roche Ltd, Les Laboratoires Servier SAS, Ono Pharmaceutical Co Ltd, and Saniona AB |
Segments Covered in the Report
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Therapy Areas Outlook
- Central Nervous System
- Genetic Disorders
- Cardiovascular
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Mechanism of Actions Outlook
- Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Antagonist)
- Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Agonist)
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Routes of Administration Outlook
- Oral
GABA(A) Receptor Subunit Alpha 5 Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5).
- Reviews of targeted therapeutics for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) therapeutics and enlists all their major and minor projects.
- Assessment of Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Cerevel Therapeutics Holdings Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ono Pharmaceutical Co Ltd
Saniona AB
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market?
The key therapy areas of the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are the central nervous system, genetic disorders, and cardiovascular.
-
What are the key mechanism of actions in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market?
The key mechanism of actions in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Antagonist) and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA Agonist).
-
What are the key routes of administration in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market?
The route of administration in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market is oral.
-
What are the key molecule types in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market?
The key molecule type in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market is small molecule.
-
Which are the key companies in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market?
The key companies in the GABA(A) Receptor Subunit Alpha 5 pipeline drugs market are AgeneBio Inc, Anvyl LLC, Cerevel Therapeutics Holdings Inc, F. Hoffmann-La Roche Ltd, Les Laboratoires Servier SAS, Ono Pharmaceutical Co Ltd, and Saniona AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.